“We are finally starting to see into the future, understanding the ways COVID-19 is changing the future of FDA regulatory process and advancing innovation to meet the needs of today’s patients. Thanks to all the attendees for such amazing questions and contributions!” commented MoFo partner and head of our FDA Regulatory + Life Sciences Compliance practice Bethany Hills at the end of our session 4 of the GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups, COVID-19: FDA and Compliance Issues with Testing, Vaccines, and Therapies.
Bethany J. Hills
Bethany advises her life sciences business clients on both pre- and post-market issues, including everything from FDA submissions and communications strategies to post-approval compliance and reimbursement issues. Her clients include medical device, drug, combination product, diagnostic, biologic, and regenerative medicine, cosmetic, dietary supplement, and food industry companies, and the investor groups focusing on these industries. Bethany leverages her deep FDA regulatory experience and exceptional knowledge More ›
Matthew A. Chivvis
Matthew protects his life sciences and high-tech clients’ intellectual property and defends his clients wrongly accused of infringement. His hearing and trial experience is extensive. Although his practice focuses on intellectual property litigation in federal and state courts, he also regularly advises clients on plant and agriculture intellectual property matters, including strategic use of plant patents, plant-variety protection certificates, and trademark rights. Matthew also More ›
Michael R. Ward
Michael R. Ward is global head of the firm’s Life Sciences Practice Group, head of the firm’s Patent Practice Group, co-chair of the firm’s Intellectual Property Practice Group and co-chair of our global AgTech + Food Industry practice. Dr. Ward is widely recognized as one of the world’s leading agriculture IP lawyers. As the founder and head of the firm’s Plant Intellectual Property Group, Dr. More ›